ライフサイエンスコーパス: gadolinium enhancement

1 , as well as the extent of necrosis (delayed gadolinium enhancement).

2 cally, and with MR imaging (with and without gadolinium enhancement).

3 f 6-month wall thickening compared with late gadolinium enhancement.

4 ncement and edema exceeding the area of late gadolinium enhancement.

5 y LIBS-MPIOs and myocardial necrosis by late gadolinium enhancement.

6 s, 114 had a visible myocardial scar by late gadolinium enhancement.

7 showed intramyocardial and pericardial late gadolinium enhancement.

8 en death risk factors and 50 (37%) with late gadolinium enhancement.

9 No subjects had late gadolinium enhancement.

10 of myocardial perfusion, function, and late gadolinium enhancement.

11 Viability was assessed using late gadolinium enhancement.

12 0.37-0.47) but not with the presence of late gadolinium enhancement.

13 acterization of replacement fibrosis by late gadolinium enhancement.

14 epared steady-state-free precession, or late gadolinium enhancement.

15 was identified by a diffuse pattern of late gadolinium enhancement.

16 with tumor progression, and tumors showed no gadolinium enhancement.

17 n, LV septal wall thickening, and LV delayed gadolinium enhancement.

18 dyskinetic area, and score of extent of late gadolinium enhancement.

19 me course than that of changes observed with gadolinium enhancement.

20 of T1 after gadolinium enhancement/T1 before gadolinium enhancement.

21 d collagen loss in terms of T1 improved with gadolinium enhancement.

22 atrophy or abnormal signal intensity and/or gadolinium enhancement.

23 hould be obtained after, rather than before, gadolinium enhancement.

24 and T2-weighted MR imaging before and after gadolinium enhancement.

25 mapping, rest first pass perfusion, and late gadolinium enhancement.

26 77.8% (14/18) of patients had focal late gadolinium enhancement.

27 terisation with a suggestive pattern of late gadolinium enhancement.

28 ovascular obstruction was assessed with late gadolinium enhancement.

29 olic function, native T1 mapping, edema, and gadolinium enhancement.

30 jects in groups 3 and 4 had evidence of late gadolinium enhancement.

31 istribution is not well visualized with late gadolinium enhancement.

32 nted with cerebral demyelinating lesions and gadolinium enhancement.

33 h those of other cardiac MR parameters (late gadolinium enhancement, 0.90; T2 ratio, 0.79; extracellu

34 ortion of total left ventricular mass (%late gadolinium enhancement; 10.4+/-13.2% versus 8.5+/-8.5%;

35 elating with the presence or absence of late gadolinium enhancement (1001+/-82 versus 891+/-38 millis

36 ger than the infarct size quantified by late gadolinium enhancement (37.2+/-11.6% versus 22.3+/-11.7%

37 ts without and in patients with evident late gadolinium enhancement (466 msec +/- 14, 406 msec +/- 59

38 of patients underwent cardiac MRI with late gadolinium enhancement 6 to 9 days after the index ST-se

39 The presence of late gadolinium enhancement (65% versus 64%; P=0.99) and the

40 uptake, as well as transmural extent of late gadolinium enhancement, acutely can identify viable myoc

41 rization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

42 ts with myocardial scar determined with late gadolinium enhancement and 286 age-, sex-, and ethnicity

43 ascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

44 ac amyloid by combining the presence of late gadolinium enhancement and an optimized T1 threshold (19

45 ic resonance showed regional transmural late gadolinium enhancement and edema exceeding the area of l

46 Both transmural extent of late gadolinium enhancement and FDG uptake on the acute scan

47 s regarding the presence of abnormal orbital gadolinium enhancement and judged them as "definitive tu

48 magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sarcoid

49 Strong lipid peaks in the absence of gadolinium enhancement and MRI-defined lesions were obse

50 nd normal myocardial regions on the basis of gadolinium enhancement and regional function.

51 e instances it is usefully complemented with gadolinium enhancement and spinal imaging.

52 g was performed as well as early and delayed gadolinium enhancement and systolic function assessment.

53 this zone was most commonly spared from late gadolinium enhancement and T2 abnormalities, typically s

54 All animals underwent MRI (late gadolinium enhancement and T2-weighted edema imaging) im

55 n-echo images were obtained before and after gadolinium enhancement and were compared regarding lesio

56 was performed to quantify regional (by late-gadolinium enhancement) and diffuse (by T1 mapping) myoc

57 ate gadolinium enhancement (ventricular late gadolinium enhancement) and diffuse fibrosis with postco

58 CMR DENSE, late gadolinium enhancement, and electrical timing together c

59 presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricular e

60 ne stress/rest perfusion, cine imaging, late gadolinium enhancement, and magnetic resonance coronary

61 enosine stress perfusion, cine imaging, late gadolinium enhancement, and MR coronary angiography.

62 , strain imaging by myocardial tagging, late gadolinium enhancement, and native T1 mapping (Shortened

63 erformed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping.

64 al associations among stress perfusion, late gadolinium enhancement, and T2 imaging were made at segm

65 Cine, stress perfusion, late gadolinium enhancement, and T2-weighted imaging techniqu

66 ocardial velocities, scar determined by late gadolinium enhancement, and wall motion abnormalities.

67 gher troponin T peak (P<0.0001), larger late gadolinium enhancement area (P<0.0001), and lower left v

68 r troponin T peak (P=0.006) but similar late gadolinium enhancement area (P=0.24) compared with those

69 and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared with 14% in HTN subj

70 ons of HCM subjects without evidence of late gadolinium enhancement, as well as of hypertensive patie

71 c magnetic resonance imaging, including late gadolinium enhancement assessment of fibrosis.

72 Transverse pancakelike gadolinium enhancement associated with and just caudal t

73 isplayed clear tumor delineation with strong gadolinium enhancement at 6 wk.

74 ing the first trimester of pregnancy or with gadolinium enhancement at any time of pregnancy is unkno

75 For active patients, defined as those with gadolinium enhancement at baseline, the median change in

76 tive/postcontrast T1 maps, T2 maps, and late gadolinium enhancement at days 1 and 21 post-MI.

77 The presence of late gadolinium enhancement at magnetic resonance imaging, a

78 The presence of late gadolinium enhancement at magnetic resonance imaging, a

79 including T2-weighted edema imaging and late gadolinium enhancement before coronary angiography.

80 The association of scar on late gadolinium enhancement cardiac magnetic resonance (LGE-C

81 Scar signal quantification using late gadolinium enhancement cardiac magnetic resonance (LGE-C

82 electrophysiology mapping) and advanced late gadolinium enhancement cardiac magnetic resonance scar i

83 uscular dystrophy, myocardial damage by late gadolinium enhancement cardiac MRI and preserved ejectio

84 Late-gadolinium-enhancement cardiac MRI (LGE-MRI) assessment

85 hteen consecutive patients referred for late gadolinium enhancement-cardiac magnetic resonance and a

86 Late gadolinium enhancement-cardiac magnetic resonance is inc

87 d by midwall hyperenhancement (MWHE) on late gadolinium enhancement cardiovascular magnetic resonance

88 he significance of fibrosis detected by late gadolinium enhancement cardiovascular magnetic resonance

89 HCM, myocardial fibrosis as measured by late gadolinium enhancement cardiovascular magnetic resonance

90 Midwall fibrosis is identified by late gadolinium enhancement cardiovascular magnetic resonance

91 sive) myocardial scarring identified by late gadolinium enhancement cardiovascular magnetic resonance

92 patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance

93 Cine and late gadolinium enhancement cardiovascular MR and 2-dimension

94 Late gadolinium enhancement-cardiovascular magnetic resonance

95 ccasion, fibroleiomyoma signal intensity and gadolinium enhancement characteristics were assessed in

96 ded, as were MR imaging signal intensity and gadolinium-enhancement characteristics.

97 Conversely, late gadolinium enhancement CMR should be postponed in the te

98 Late gadolinium enhancement CMR was performed in 30 patients

99 Cine and late gadolinium enhancement CMR were performed in 333 consecu

100 sine stress 3D myocardial perfusion and late gadolinium enhancement CMR.

101 The edema volume in late gadolinium enhancement correlated well with edema volume

102 Heterogeneous gadolinium enhancement, cortical thickness, round shape,

103 Infarct size (late gadolinium enhancement) decreased after CSC infusion (by

104 Indexed MRI-late gadolinium enhancement-defined infarct size was 18.3 (IQ

105 In individuals without a late gadolinium enhancement-defined myocardial scar (n = 1131

106 CMR-LVEF </=35% or CMR-LVEF </=35% plus late gadolinium enhancement detection showed a higher perform

107 ents with intermediate transmurality of late gadolinium enhancement, dobutamine response improves the

108 l perfusion, microvascular obstruction, late gadolinium enhancement, edema, and intramyocardial hemor

109 ate analysis, (18)F-FDG PET, T1-weighted MRI gadolinium enhancement (excluding nonenhancing resection

110 Dorsal cord subpial gadolinium enhancement extending >/=2 vertebral segments

111 nstrated that (18)F-FDG extent exceeded late gadolinium enhancement extent (33.2+/-16.2% left ventric

112 Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were assessed.

113 Late gadolinium enhancement for replacement fibrosis was dete

114 tricular (LV) volumes and function, and late gadolinium enhancement for the detection of myocardial s

115 98% completed stress CMR, 82% completed late gadolinium enhancement for viability, 94% completed live

116 higher baseline hs-cTnT categories and late gadolinium enhancement (>/=7.42 ng/L versus <limit of de

117 tio=2.18 [1.3-3.8]) and the presence of late gadolinium enhancement (hazard ratio=2.2 [1.4-3.6]) were

118 Late gadolinium enhancement, however, relies on the regional

119 (0%) of the control subjects had myocardial gadolinium enhancement; however, all patients (100%) wit

120 In parallel, late gadolinium enhancement identified the extent of myocardi

121 crovascular obstruction region on acute late gadolinium enhancement images acquired 26.1 minutes afte

122 Late gadolinium enhancement images were acquired to detect my

123 Late gadolinium enhancement images were blindly interpreted f

124 enosis was removed, and T2-weighted and late-gadolinium-enhancement images were acquired.

125 um were identified from postreperfusion late-gadolinium-enhancement images.

126 Late gadolinium enhancement imaging is an established method

127 Late gadolinium enhancement imaging was abnormal in 79 patien

128 Quantification of fibrosis from late gadolinium enhancement imaging was incrementally perform

129 or first pass myocardial perfusion, and late gadolinium enhancement imaging), transthoracic echocardi

130 of cine, rest first-pass perfusion, and late gadolinium enhancement imaging.

131 Gadolinium enhancement improved the delineation of norma

132 etic resonance imaging was positive for late gadolinium enhancement in 21 of 23 (91%) patients, where

133 haracteristic pancakelike transverse band of gadolinium enhancement in 41 (73%), typically immediatel

134 One subject in group 2 had late gadolinium enhancement in a noncoronary distribution, an

135 normal LV contractility and absence of late gadolinium enhancement in all but one patient.

136 There was no late gadolinium enhancement in any of the participants before

137 Emerging data suggest a key role for late gadolinium enhancement in detection of left ventricular

138 le for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and noninvasiv

139 Gadolinium enhancement in lesions that are hyperintense

140 increase in the frequency of noninfarct late gadolinium enhancement in PA (70%) when compared with es

141 cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left ventricul

142 CMR at 1.5 T including cine, DENSE, and late gadolinium enhancement in subjects >45 years.

143 in early disease stages and complements late gadolinium enhancement in visualization of the regional

144 rted for any mice, and the first use of late-gadolinium-enhancement in a mouse model of congenital ca

145 al injury could improve the accuracy of late gadolinium-enhancement in predicting functional recovery

146 Cardiac MRI studies showed late gadolinium enhancement, indicating myocardial fibrosis,

147 etic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular fibros

148 sion wave was inversely correlated with late-gadolinium enhancement infarct mass (r=-0.81; P<0.0001)

149 a CMR diagnosis and some CMR parameters-late gadolinium enhancement, left ventricular ejection fracti

150 Cardiac magnetic resonance late gadolinium enhancement (LGE) and feature-tracking are ca

151 magnetic resonance imaging pericardial late gadolinium enhancement (LGE) and inflammatory biomarkers

152 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE had s

153 resonance (CMR) protocol incorporating late gadolinium enhancement (LGE) and magnetic resonance CA a

154 Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) and T1 mapping, is emerging

155 ameters at diagnosis predict dynamic of late gadolinium enhancement (LGE) as persistent LGE has been

156 nction and tissue characterization with late gadolinium enhancement (LGE) as well as T1 and T2 mappin

157 ere are scarce data on the influence of late gadolinium enhancement (LGE) assessed by cardiovascular

158 t ventricular quantitative analysis and late gadolinium enhancement (LGE) assessments and analyzed th

159 ce of ventricular fatty replacement and late gadolinium enhancement (LGE) at cardiac magnetic resonan

160 Late gadolinium enhancement (LGE) border zone on cardiac magn

161 t studies have evaluated the ability of late gadolinium enhancement (LGE) by cardiac magnetic resonan

162 Prior studies have shown that late gadolinium enhancement (LGE) by cardiac magnetic resonan

163 Late gadolinium enhancement (LGE) by cardiac MR (CMR) is a pr

164 ined whether the presence and extent of late gadolinium enhancement (LGE) by cardiovascular magnetic

165 eported an inverse relationship between late gadolinium enhancement (LGE) cardiac magnetic resonance

166 Late gadolinium enhancement (LGE) cardiovascular magnetic res

167 hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magnetic res

168 hypothesized that fibrosis detected by late gadolinium enhancement (LGE) cardiovascular magnetic res

169 yocardial fibrosis can be visualized by late gadolinium enhancement (LGE) cardiovascular magnetic res

170 We investigated whether late gadolinium enhancement (LGE) cardiovascular magnetic res

171 h cardiovascular magnetic resonance for late gadolinium enhancement (LGE) detection and quantificatio

172 Stress CMR with late gadolinium enhancement (LGE) has also shown that MBF is

173 levation myocardial infarction (STEMI), late gadolinium enhancement (LGE) has been demonstrated to ov

174 cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in vivo m

175 of cardiac magnetic resonance (CMR) and late gadolinium enhancement (LGE) has not been clarified in a

176 have demonstrated regional left atrial late gadolinium enhancement (LGE) heterogeneity on magnetic r

177 e inversion-recovery (STIR) images, and late gadolinium enhancement (LGE) images were acquired.

178 Although late gadolinium enhancement (LGE) imaging by cardiac magnetic

179 om flow-limiting coronary stenosis, CMR late gadolinium enhancement (LGE) imaging is currently the mo

180 Late gadolinium enhancement (LGE) imaging overestimates acute

181 ing cardiac magnetic resonance imaging, late gadolinium enhancement (LGE) in 17 patients, and T2 sign

182 extracellular volume fraction (ECV) and late gadolinium enhancement (LGE) in children and young adult

183 c significance of left ventricular (LV) late gadolinium enhancement (LGE) in patients with atrial fib

184 +/- 10.9 years), 25 (28%) had positive late gadolinium enhancement (LGE) in the ventricular myocardi

185 Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for

186 art of a CMR protocol including MPI and late gadolinium enhancement (LGE) is not well established.

187 cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is unresolved.

188 assess acute ablation injuries seen on late gadolinium enhancement (LGE) magnetic resonance imaging

189 Myocardial fibrosis was detected by late gadolinium enhancement (LGE) MRI, and myocardial perfusi

190 s that magnetic resonance imaging (MRI) late gadolinium enhancement (LGE) of the coronary vessel wall

191 isolated LV subepicardial/midmyocardial late gadolinium enhancement (LGE) on contrast-enhanced cardia

192 ted myocarditis underwent CMR including late gadolinium enhancement (LGE) parameters between 2002 and

193 d that achieved by the well-established late gadolinium enhancement (LGE) technique (which detects fo

194 The presence of late gadolinium enhancement (LGE) yields a hazard ratio of 8.

195 dial damage, defined by the presence of late gadolinium enhancement (LGE), (2) quantify their risk of

196 rest, hyperemia perfusion defect (PD), late gadolinium enhancement (LGE), and inducible WMA were ana

197 (HCM) myocardial fibrosis, detected by late gadolinium enhancement (LGE), is associated to a progres

198 of 1,228 patients with AF who underwent late gadolinium enhancement (LGE)-cardiac magnetic resonance

199 is of the myocardium is detectable with late gadolinium enhancement (LGE).

200 t of left ventricular (LV) function and late gadolinium enhancement (LGE).

201 hy, and cardiac magnetic resonance with late gadolinium enhancement (LGE); all 3 tests were <24 hours

202 ge transmural (volume of enhancement on late gadolinium enhancement [LGE] images >20%, n = 72) or sma

203 arated imaging, focal fibrosis imaging (late gadolinium enhancement [LGE]), and (1)H magnetic resonan

204 ft ventricular function, and myocardial late gadolinium enhancement [LGE]), and metabolic parameters

205 rs) underwent T2-weighted, tagging, and late gadolinium enhancement magnetic resonance imaging at thr

206 icrovascular resistance correlated with late-gadolinium enhancement mass (r=0.48; P=0.03) but not lef

207 cular ejection fraction, and percentage late-gadolinium enhancement mass were 1.35+/-1.21 microg/L, 5

208 e-breathing, motion-corrected, averaged late-gadolinium-enhancement (moco-LGE) cardiovascular MR may

209 dance, and gap lengths determined using late gadolinium enhancement MR images were correlated with ga

210 T2-weighted, native T1/T2 mapping, and late gadolinium enhancement MR imaging.

211 We hypothesized that late gadolinium enhancement MRI (LGE-MRI) can identify left a

212 tip placement through coregistration of late gadolinium enhancement MRI and cardiac computed tomograp

213 erize different areas of enhancement in late gadolinium enhancement MRI done immediately after ablati

214 -tesla MRI system where high-resolution late gadolinium enhancement MRI was used to identify the gap.

215 ents receiving CRT underwent preimplant late gadolinium enhancement MRI, postimplant cardiac CT, and

216 gaps up to 1.4 mm were identified using late gadolinium enhancement MRI.

217 with clinical cardiovascular disease or late gadolinium enhancement (n = 167), and after replacing LV

218 o), early gadolinium enhancement ratio, late gadolinium enhancement, native T1 relaxation times, and

219 asured in 27 subjects, all of whom were late gadolinium enhancement negative.

220 Most of these patients were late gadolinium enhancement negative.

221 rea of gadolinium enhancement (t(1)) and two gadolinium enhancement-negative follow-up evaluations af

222 ted by rest and stress perfusion imaging and gadolinium enhancement obtained 2 min.

223 At baseline, a lower extent of late gadolinium enhancement (odds ratio [OR]: 0.67 [95% confi

224 Prolongation of the T2 relaxation time and gadolinium enhancement of denervated muscle develop in p

225 Gadolinium enhancement of myocardial infarction was init

226 The results showed, in all 12 pigs, the gadolinium enhancement of the target vessel walls on MR

227 iRNAs were also decreased in patients with a gadolinium enhancement on brain magnetic resonance imagi

228 years) arrhythmic MVP patients with LV late gadolinium enhancement on cardiac magnetic resonance and

229 fraction was 51% (+/-17%), and 32% had late gadolinium enhancement on cardiac magnetic resonance.

230 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic resona

231 letes but none of the controls revealed late gadolinium enhancement on cardiovascular magnetic resona

232 ere required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MR

233 atecholamine levels, RV dilatation, and late gadolinium enhancement on MRI, increased (18)fluorodeoxy

234 in T2 signal abnormality +/- decrease in T1 gadolinium enhancement, on stable or reduced steroid dos

235 Diabetics without late gadolinium enhancement or inducible ischemia had a low a

236 associated with increased occurrence of late gadolinium enhancement (P=0.004).

237 as mainly asymmetrical, and had similar late gadolinium enhancement patterns.

238 Signal intensity characteristics and gadolinium-enhancement patterns in 84 aneurysms (62 pati

239 hesis, joint disorganization and debris, and gadolinium-enhancement patterns of vertebral bodies and

240 All patients had symmetric curvilinear gadolinium enhancement peppering the pons and extending

241 with both imaging modalities and higher late gadolinium enhancement per-patient prevalence as compare

242 regression analysis after adjusting for late gadolinium enhancement, perfusion, and wall motion score

243 Gadolinium enhancement persisted in 75% at 12 months, ra

244 ll patients with ECG strain had midwall late gadolinium enhancement (positive and negative predictive

245 ntified by wall motion abnormalities or late gadolinium-enhancement positivity.

246 In those undergoing CA, the absence of late gadolinium enhancement predicted greater improvements in

247 With gadolinium enhancement, proteoglycan depletion was assoc

248 agnetic resonance evidence of regional (late-gadolinium enhancement quantity, 6.4+/-8.0%) and diffuse

249 nd closely correlated with the areas of late gadolinium enhancement (R 0.98) with a small bias of 2.0

250 ; extracellular volume fraction, 0.71; early gadolinium enhancement ratio, 0.63; P = .390, .018, .002

251 , 1.6+/-0.3 versus 1.4+/-0.3; P=0.046; early gadolinium enhancement ratio, 3.1+/-1.2 versus 2.1+/-0.6

252 was superior to that with T2 ratio and early gadolinium enhancement ratio, and specificity was higher

253 ery signal intensity ratio (T2 ratio), early gadolinium enhancement ratio, late gadolinium enhancemen

254 Myocardial fibrosis was determined with late gadolinium enhancement (replacement fibrosis) and T1 map

255 1.8 mV; 3 abnormal SAECG parameters; delayed gadolinium enhancement, RV ejection fraction </=45%, or

256 ological abnormalities colocalized with late gadolinium enhancement scar, indicating a relationship w

257 inetic area r=-0.49, P<0.0001; and RVOT late gadolinium enhancement score r=-0.33, P=0.01.

258 rential strain (Ecc), segmental area of late gadolinium-enhancement (SEE), microvascular obstruction,

259 ces, and infarct size was determined by late gadolinium enhancement sequences and creatine kinase rel

260 ntal comparison of (18)F-FDG-uptake and late gadolinium enhancement showed substantial overlap (kappa

261 fter excluding myocardial segments with late gadolinium enhancement, significant relationships betwee

262 n seen in patients with and without baseline gadolinium enhancement suggests that part of the cerebra

263 brain scan positive for at least one area of gadolinium enhancement (t(1)) and two gadolinium enhance

264 en it was expressed as the ratio of T1 after gadolinium enhancement/T1 before gadolinium enhancement.

265 0.016) were higher in MVP patients with late gadolinium enhancement than in those without.

266 thickness was greater in segments with late gadolinium enhancement than without (20 +/- 6 mm vs. 16

267 myocardial fibrosis as demonstrated by late gadolinium enhancement using cardiac magnetic resonance

268 tifying focal ventricular fibrosis with late gadolinium enhancement (ventricular late gadolinium enha

269 cose score was highest in segments with late gadolinium enhancement versus edema only and remote (med

270 was in good agreement with the 6-month late gadolinium enhancement volume (r=0.99) and correlated st

271 In addition, late gadolinium enhancement was also assessed.

272 The presence of late gadolinium enhancement was also significantly associated

273 Late gadolinium enhancement was assessed by using gradient-ec

274 The value of gadolinium enhancement was assessed by using receiver op

275 Late gadolinium enhancement was assessed with CMR.

276 l LS and CS 2DST and 2DTagg to identify late gadolinium enhancement was compared using receiver opera

277 Myocardial fibrosis by late gadolinium enhancement was detected in 15.8% of the pati

278 1) spondylotic myelopathy was suspected, (2) gadolinium enhancement was detected, and (3) spinal surg

279 Global subendocardial late gadolinium enhancement was found in 20 amyloid patients

280 Indeed, late gadolinium enhancement was independently associated with

281 The degree of gadolinium enhancement was not correlated with fibroleio

282 ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid patie

283 Late gadolinium enhancement was present in >60% of overt pati

284 r ejection fraction was 61 +/- 12%; and late gadolinium enhancement was present in 29% and ischemia i

285 Myocardial late gadolinium enhancement was present in 4 (27%) of 15 pati

286 que rupture was found in nearly 40% and late gadolinium enhancement was seen in nearly 40%, with litt

287 farcted versus noninfarcted segments by late gadolinium enhancement was similarly good for regional L

288 er injection and imaging of LIBS-MPIOs, late gadolinium enhancement was used to depict myocardial nec

289 Regional left ventricular function and late-gadolinium enhancement were assessed by cardiac magnetic

290 entricular dilation and the presence of late gadolinium enhancement were inversely correlated to hepa

291 age: 40 years) MVP patients without LV late gadolinium enhancement were investigated by morphofuncti

292 Both ECV and late gadolinium enhancement were more extensive in sarcomeric

293 el, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for each s

294 patients with SCD (25%) had evidence of late gadolinium enhancement, whereas only 1 patient had evide

295 egional diffuse fibrosis not visible by late gadolinium enhancement, which was associated with impair

296 Late gadolinium enhancement with CMR was performed in 90 pati